Company: Boehringer Ingelheim
Drug Type: Small Molecule
Conditions: ALS, Heart Arrhythmia, Muscle Cramps, Neuropathic Pain
Mechanism Type: Neuronal hyperexcitability
Mechanism: Mexiletine is a sodium channel blocker that may reduce neuronal hyperexcitability by reducing sodium ion influx (the persistent sodium current).
U.S. Status for ALS: Phase II
 A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression. Neurology. 2016 Apr 19;86(16):1474-81.
 Mexiletine in Sporadic Amyotrophic Lateral Sclerosis. ClinicalTrials.gov, 23 August 2017. Accessed on 7 March 2017 from https://clinicaltrials.gov/ct2/show/NCT02781454.
Last updated March 7th, 2017